Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote “FOR” All Proxy Proposals at the Special Meeting to be held on January 10, 2024
NEW YORK, Jan. 2, 2024 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL) (“Seelos”), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that Institutional Shareholder Services (“ISS”), a leading independent proxy voting and corporate governance advisory firm, recommends Seelos stockholders vote “FOR” all proposals at the Special Meeting of Stockholders, including management’s proposal to increase the number of authorized shares of common stock. The Special Meeting is scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.com/SEEL2024SM, on Wednesday, January 10, 2024 at 8:00 a.m., Eastern Time.
Related news for (SEEL)
- seelos therapeutics announces 1-for-16 reverse stock split
- 24/7 Market News- Seelos Therapeutics Signs MTA with U.S. Army Medical Materiel Development Activity for Potential PTSD treatment
- seelos therapeutics announces the signing of a material transfer agreement with u.s. army medical materiel development activity (usammda) to evaluate sls-002 for treatment of ptsd
- 24/7 Market News Snapshot 24 September, 2024 – Seelos Therapeutics, Inc. Common Stock (NASDAQ:SEEL)
- Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules